Atacicept is a recombinant fusion protein that binds to and inhibits the activity of BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand).
FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy Desi ...
Enable Injections announced today that it received a commitment from Sanofi for a $30 million investment to drive growth.
Alex Terrible addresses critics in a candid new statement, rejecting his "poser tough guy" label and opening up about ...
The global respiratory disease vaccine market size was valued at USD 65.72 billion in 2025 and is predicted to hit around USD ...
Abstract: This study used a 2.4 GHz four-channel phase- and quadrature self-injection-locked radar to detect vital signs of a moving person. A modified principal component analysis (MPCA) method was ...
Abstract: Noncontact vital sign sensing usually utilizes highly sensitive Doppler radars. Self-injection-locked (SIL) radars have been studied to have better sensing capabilities than traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback